Edition:
India

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.72USD
2:29am IST
Change (% chg)

$0.03 (+1.78%)
Prev Close
$1.69
Open
$1.68
Day's High
$1.73
Day's Low
$1.65
Volume
20,111
Avg. Vol
92,974
52-wk High
$4.68
52-wk Low
$1.35

Select another date:

Wed, Nov 15 2017

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1‍​

* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1‍​ Further company coverage:

BRIEF-Imprimis Pharmaceuticals to offer compounded Cyclosporine alternative to Restasis

* Imprimis Pharmaceuticals-‍making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis​ Source text for Eikon: Further company coverage:

BRIEF-FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

BRIEF-Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit

* Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​

BRIEF-Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida

* Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC

BRIEF-Imprimis Pharmaceuticals Q2 earnings per share $0.07

* Imprimis pharmaceuticals announces second quarter 2017 financial results

BRIEF-Imprimis provides statement regarding curcumin emulsion FDA medwatch notice

* Imprimis statement regarding curcumin emulsion FDA medwatch notice

BRIEF-Imprimis Pharmaceuticals announces $16 mln debt facility with SWK Holdings

* Imprimis Pharmaceuticals announces $16 million debt facility with SWK Holdings

Select another date: